

Stratech

stratech.co.uk/signalchem info@stratech.co.uk

2019-nCoV Spike protein RBD, HIS Tag Catalog No: C19SD-G241H

The spike glycoprotein (S) of coronavirus belongs to the type I transmembrane protein containing two subunits, S1 and S2, and the entry of SARS-CoV-2 into the cells is mediated by effective binding of the viral Spike (S) protein to human ACE2 cell receptor. A receptor binding domain (RBD) of S1 can recognize the cell surface receptor and the mutation of RBD could cause higher motility rate, making this viral protein a prime target in studying the infection, and developing safe therapeutics against the ongoing COVID-19 pandemic. SignalChem's Recombinant 2019-nCoV Spike protein S1 subunit, receptor-binding domain (RBD) (319-541) was expressed in CHO cells using a C-terminal his tag.

Unique Selling Points



Fully functional estimated using ELISA assay



Strong binding affinity to human ACE2 protein



The purity was determined to be approx. 90%



Effective tool for SARS-CoV-2 research

Competitors







Scientists developing targeted anti-Spike protein antiviral therapies



Target Customers

Biopharmaceutical companies developing vaccines







Universities investi-SARS-COV-2 structure gating SARS-CoV-2

Government research organizations

Scientists studying and mode of actions